ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾
ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÐÂÎÅ
Group News
¡¾AACR 2025¡¿ÉÏÏ¸Ç°ÑØÍ»ÆÆÒ» | È«ÇòÊ×´´6Сʱ¼«ËÙÖÆ±¸£ºJL-ÉÁCAR-T?ÖúÁ¦¶ÌÖÜÆÚ¡¢µÍ±¾Ç®¡¢³¤Ò©Ð§ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ò©Î↑·¢
2025-05-15

4ÔÂ25ÈÕ-30ÈÕ£¬£¬£¬£¬£¬ £¬±¸ÊܹØ×¢µÄÃÀ¹ú°©Ö¢Ñо¿Ð­»á£¨AACR£©Äê»áÔÚÃÀ¹úÖ¥¼Ó¸çÕÙ¿ª£¬£¬£¬£¬£¬ £¬±¾½ì¾Û»áÒԓͳһ°©Ö¢¿ÆÑ§Óëҽѧ£ºÒ»Á¬Á¢Òì´øÀ´Àå¸ï”ΪÖ÷Ìâ¡£¡£¡£¡£¡£¡£±ü³Ö“ÁÆÐ§ÎªºË£¬£¬£¬£¬£¬ £¬ÀèÃñ¿É¼°”µÄÒ©Î↑·¢ÀíÄ£¬£¬£¬£¬ £¬ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ò»Á¬Íƶ¯JL-ÉÁCAR-T™Îª½¹µãµÄÒªº¦ÊÖÒÕÆ½Ì¨¿ª·¢£¬£¬£¬£¬£¬ £¬ÊµÏÖÔ­´´·Ç²¡¶¾ÔØÌå»ùÒòдÈëÊÖÒÕ¡¢ÄÉÃ׿¹ÌåVHHMAb®ÊÖÒյȵײãÊÖÒÕµÄÒ»Á¬Í»ÆÆ£¬£¬£¬£¬£¬ £¬¼ÓËÙÁ¢ÒìÖÎÁÆÒ©Î↑·¢Àú³Ì¡£¡£¡£¡£¡£¡£±¾´Î¾Û»á£¬£¬£¬£¬£¬ £¬¼¯ÍʲÓÐ5Ïî×îÐÂÑо¿Ð§¹û»ñÑûÏÖ³¡Õ¹Ê¾£¬£¬£¬£¬£¬ £¬ÁýÕÖ´Óµ×²ãÆ½Ì¨Í»ÆÆµ½ÓÅÊÆ¿¹Ìå·¢Ã÷£¬£¬£¬£¬£¬ £¬ÔÙ¹âÁÙ´²Ó¦ÓÃת»¯µÄÍêÕûÒ©Î↑·¢ÏµÍ³¡£¡£¡£¡£¡£¡£³ä·ÖÕ¹ÏÖÁ˼¯ÍÅÔÚË¢ÐÂCAR-TµÈÁ¢ÒìÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ò©Îï¿É¼°ÐÔºÍÖÎÓúÐÔ·½ÃæµÄǰհ½á¹¹¼°ÁÉÀ«Ô¶¾°¡£¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

BZE2204ΪһÏîȫеÄÎÞÐèÌåÍâ×÷ÓýµÄ³¬¿ìËٷDz¡¶¾ÔØÌåÈý°ÐµãѪҺÁöCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÏîÄ¿¡£¡£¡£¡£¡£¡£ÓÉÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÍŽáÉϺ£´óѧÁ¥ÊôÃϳ¬Ö×ÁöÒ½Ôº¼°ÃÀ¹ú×Ó¹«Ë¾Chantibody£¨CHANTIBODY THERAPEUTICS INC.£©ÅäºÏ¿ªÕ¹¡£¡£¡£¡£¡£¡£

 

BZE2204½ÓÄɼ¯ÍÅJL-ÉÁCAR-T™ÖƱ¸¹¤ÒÕÆ½Ì¨£¬£¬£¬£¬£¬ £¬×î¶ÌÖÆ±¸¹¤ÒÕµÄʱ¼äΪ6Сʱ£¨6h£©Íê³É´Óµ¥²ÉѪµ½ÖƼÁµÄÈ«Àú³Ì£¬£¬£¬£¬£¬ £¬×îºéÁ÷ƽ°ü¹ÜTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄ¸ÉÐÔºÍÀ©ÔöÄÜÁ¦£¬£¬£¬£¬£¬ £¬ÔÚÁÙ´²Ç°¶¯ÎïÊý¾ÝºÍIITÁÙ´²ÊµÑéÉ϶¼Õ¹ÏÖ³öÁËÓÅÒìµÄ¿¹Ö×ÁöЧ¹û£¬£¬£¬£¬£¬ £¬ÊÇÉÁCAR-TÖÆ±¸ÊÖÒÕÁ¢ÒìÓë¶à°ÐµãCARÉè¼ÆÁ¢ÒìµÄÓлúÍŽᡣ¡£¡£¡£¡£¡£

 

BZE2204ÌåÄÚÀ©ÔöÄÜÁ¦Ç¿£¬£¬£¬£¬£¬ £¬ÒÔͨÀýÊÐÊÛCAR-T¼ÁÁ¿µÄ1/40£¬£¬£¬£¬£¬ £¬µÖ´ïͨÀý¼ÁÁ¿²úÆ·30-200±¶µÄ Cmax (CAR-T/ul)¡¢17-150±¶µÄAUC(CAR-T/ul*d)¡£¡£¡£¡£¡£¡£ÏÖÔÚ6h¹¤ÒÕ¿ªÕ¹µÄIITÁÙ´²ÊµÑéÖУ¬£¬£¬£¬£¬ £¬ÔÚÄÑÖθ´·¢ÃÖÂþ´óBÁܰÍÁö£¨r/r NHL£©Ä©Ïß3Àý»¼ÕßÖеִïÁÙ´²¿Í¹Û»º½âÂÊORR=100%£¬£¬£¬£¬£¬ £¬ÍêÈ«»º½âÂÊ£¨CR£©½ü70%£¨×èÖ¹·¢¸åʱÒѸüÐÂÖÁCR=100%£©£¬£¬£¬£¬£¬ £¬ÇÒ¶¾¸±×÷Óü«Ð¡£¡£¡£¡£¡£¡£¬£¬£¬£¬£¬ £¬ÎÞÈý¼¶»òÒÔÉÏCRS£¬£¬£¬£¬£¬ £¬ÎÞDLT¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»¼Õß»ØÊäºó»Ö¸´ºÃ£¬£¬£¬£¬£¬ £¬Ò»Á¬»º½â±ÈÀý¸ß¡£¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

ÕªÒªºÅ£º3173

 

ÕªÒªÎÊÌ⣺

JL-Lightning CAR-T£¬£¬£¬£¬£¬ £¬a Next Generation Non-viral CAR-T without In-Vitro Culturing Procedure, Shows High Clinical Efficacy, Good Safety with Low Dosage

 

ÕªÒªÄÚÈÝ£º

BZE2204ÊÇÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾´îÔØJL-ÉÁCAR-T™ÊÖÒÕÆ½Ì¨µÄÈý°ÐµãѪҺÖ×ÁöCAR-T²úÆ·£¬£¬£¬£¬£¬ £¬²úÆ·ÓÉanti-CD19, CD22 ºÍ BCMA Èý¸öVHH×é³É£¬£¬£¬£¬£¬ £¬ÒÔ4-1BB ºÍCD3ζ×÷Ϊ°ûÄڽṹÓò¡£¡£¡£¡£¡£¡£´ËÉè¼ÆÀíÄ£¬£¬£¬£¬ £¬ÊÇΪÁËʹ²úÆ·ÄÜÉî¶ÈɱÉ˸÷½×¶ÎµÄBÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬ £¬µÖ´ï¼²²¡³¹µ×»º½âµÄЧ¹û¡£¡£¡£¡£¡£¡£Í¬Ê±£¬£¬£¬£¬£¬ £¬¶àCARÉè¼ÆÄÜÓÐÓñÜÃâCD19ÒõÐÔµÄѪҺÖ×Áö¸´·¢£¬£¬£¬£¬£¬ £¬ÑÓÉìÎÞÏ£ÍûÉúÑÄÆÚ£¨PFS£©£¬£¬£¬£¬£¬ £¬Ê¹»¼ÕßÓиü´óµÄ»ñÒæ¡£¡£¡£¡£¡£¡£Í¬Ê±£¬£¬£¬£¬£¬ £¬ÏîÄ¿½ÓÄÉÓµÓÐ×ÔÖ÷֪ʶ²úȨµÄJLת×ùø¾ÙÐÐת×ù£¬£¬£¬£¬£¬ £¬Ïà¶ÔÊÐÊÛÆäËûת×ù×ÓЧÂʸü¸ß£¬£¬£¬£¬£¬ £¬¶¾ÐÔ¸üµÍ£¬£¬£¬£¬£¬ £¬Çå¾²£¨ÎÞ²åÈëÆ«ºÃ£©¸ßЧ¡£¡£¡£¡£¡£¡£×ÔÓÐ֪ʶ²úȨµÄ“Tini-Plasmid”ϵͳ£¨Ì«ÖÊÁ££© Ò²ÒòÆä¼«Ð¡µÄ¹Ç¼Ü¾Þϸ£¡£¡£¡£¡£¡£¨~500bp£©ÖúÁ¦¸ßЧµÍ¶¾µÄ·Ç²¡¶¾CAR»ùÒòתȾ¡£¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ BZE2204ÏîÄ¿µÄ·Ö×ÓÉè¼ÆÓëת×ùÊÖÒÕÆ½Ì¨

 

¹«Ë¾¶À´´µÄJL-Lightning™ÎÞ×÷Óý³¬¿ìËٷDz¡¶¾CAR-TÖÆ±¸Æ½Ì¨£¬£¬£¬£¬£¬ £¬Ê¹ÓÃÉÏÊöµÄת×ùøºÍÌ«ÖÊÁ£ÏµÍ³£¬£¬£¬£¬£¬ £¬½«ÊÐÊÛ²úÆ·¹Å°å¹¤ÒÕµÄ9-11ÌìÖÆ±¸Ê±¼äËõ¶Ìµ½30h£¨V-30h£©ºÍ6h£¨V-6h£©.ͨ¹ýËõ¶ÌÌåÍâ×÷Óýʱ¼ä£¬£¬£¬£¬£¬ £¬ÔÚ°ü¹Ü»îÂÊ¡¢×ªÈ¾Ð§ÂʺÍCAR-T¹¦Ð§µÄÌõ¼þÏ£¬£¬£¬£¬£¬ £¬´ó·ùÌá¸ßCAR-T²úÆ·µÄ¸ÉÐÔ±íÐÍ£¨Tscm+Tcm£©£¬£¬£¬£¬£¬ £¬ÌáÉýÌåÄÚÀ©ÔöDZÁ¦£¬£¬£¬£¬£¬ £¬´Ó¶øÊ¹µÃÁÙ´²»ØÊäºóÄÜÔÚ¸üµÍµÄ¼ÁÁ¿Ï»ñµÃ¸ü¸ßµÄÒ©´ú¶¯Á¦Ñ§Êý¾ÝºÍ¸ü¼ÑµÄÁÙ´²ÁÆÐ§¡£¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ JL-Lightning™ÎÞ×÷Óý³¬¿ìËٷDz¡¶¾CAR-TÖÆ±¸Æ½Ì¨

 

ÁÙ´²Ç°¶¯ÎïÊý¾ÝÏÔʾ£¬£¬£¬£¬£¬ £¬BZE2204ÔÚ¼«µÍ¼ÁÁ¿Ï£¨1E5 CAR-T/mice£©¿ÉÒÔʹRajiÖ×ÁöÏûÍË£¨CD19+CD22+£©£¬£¬£¬£¬£¬ £¬Ö×ÁöÏûÍË·ºÆð¼ÁÁ¿ÒÀÀµ¡£¡£¡£¡£¡£¡£Ð¡ÊóµÄÉúÑÄÇúÏßչʾ²úÆ·ÓÅÒìµÄÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£CAR-TÌåÄÚÀ©ÔöÊý¾ÝÒ²ÏÔʾ²úÆ·¼«¼ÑµÄÀ©ÔöЧÂÊ£¬£¬£¬£¬£¬ £¬ÊǵͼÁÁ¿Ï¿ØÖÆÖ×ÁöÉú³¤µÄÖ÷ÒªÒòËØ¡£¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ÁÙ´²Ç°ÌåÄÚʵÑéÊý¾Ý£¨RajiÖ×ÁöÄ£×Ó£©

 

ÁÙ´²Ç°¶¯ÎïÊý¾ÝÏÔʾ£¬£¬£¬£¬£¬ £¬BZE2204ÄܸßЧ¿ØÖÆBCMA+µÄMM1SÖ×ÁöÄ£×ÓÔÚСÊóÌåÄÚµÄÉú³¤¡£¡£¡£¡£¡£¡£Êý¾Ý±ÈÕÕÁËÁ½ÖÖBCMAµ¥±í´ïµÄCAR-T£¨ÎÒ¹«Ë¾µÄBCMA-CAR-TºÍÊÐÊÛ¾ºÆ·BCMA CAR-T£©ºÍBZE2204Èý°ÐµãCAR-TµÄÖ×ÁöÒÖÖÆÐ§ÂÊ¡£¡£¡£¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬£¬£¬ £¬BZE2204²úÆ·µÄÈý°ÐµãCAR-TÔÚÀ©ÔöºÍÖ×ÁöÒÖÖÆÐ§ÂÊÉÏÓÅÓÚµ¥BCMA CAR-T£¨BCMA-CAR·Ö×ÓÏàͬ£©£¬£¬£¬£¬£¬ £¬Á½¿î²úÆ·ÓÅÓÚÊÐÊÛµÄBCMA-CAR-T²úÆ·¡£¡£¡£¡£¡£¡£BZE2204²úÆ·¸üչʾÁËÓÅÒìµÄ·À¸´·¢Ð§¹û£¨d21¼°ÒԺ󣩣¬£¬£¬£¬£¬ £¬Ïà¶Ôµ¥°ÐµãBCMA-CAR-T£¬£¬£¬£¬£¬ £¬±¾²úÆ·Äܸü³¤Ê±¼äµÄÒÖÖÆÖ×Áö¸´·¢£¬£¬£¬£¬£¬ £¬Ô¤Ê¾×ÅÁÙ´²¿ÉÄÜÓиü³¤µÄÎÞÏ£ÍûÉúÑÄÆÚ»ñÒæ¡£¡£¡£¡£¡£¡£Ð¡ÊóµÄÉúÑÄÇúÏßͬʱչʾ²úÆ·ÓÅÒìµÄÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ÁÙ´²Ç°ÌåÄÚʵÑéÊý¾Ý£¨MM1SÖ×ÁöÄ£×Ó£©

 

ÁÙ´²¼Æ»®Éè¼ÆÓëÖмÁÁ¿×飨5E4 CAR-T/kg£©ÔÚV-30ºÍV-6hÁ½¸ö¹¤ÒÕϵÄIITÁÙ´²Êý¾Ý¡£¡£¡£¡£¡£¡£Êý¾ÝÏÔʾÖмÁÁ¿×é6Ãû»¼ÕßORR¾ùΪ100%£¬£¬£¬£¬£¬ £¬CR%=67%£¨×èÖ¹·¢¸åʱ£¬£¬£¬£¬£¬ £¬V-6hµÄÈýÃû»¼ÕßÒѸ濢ÍêÈ«»º½âÂÊ£¨CR£©=100%£©.V-30h¹¤ÒÕÖÐδ¸æ¿¢CRµÄ»¼ÕßÖ×Áö¸ººÉ¼«´ó£¨µ¥¸öÖ×Áö¸ººÉÁè¼Ý7000mm2£©£¬£¬£¬£¬£¬ £¬¾­ÓÉÖÎÁÆÖ×ÁöÒѾ­ÏûÍËÁè¼Ý90%¡£¡£¡£¡£¡£¡£²úÆ·Çå¾²ÐÔÓÅÒ죬£¬£¬£¬£¬ £¬ËùÓл¼Õß¾ùÖ»ÓÐG1 CRS£¬£¬£¬£¬£¬ £¬Ö»ÓÐÒ»Àý»¼Õß·ºÆðG3 ICANS²¢ÔÚÁÙ´²¸ÉÔ¤1ÌìÒԺ󻺽⡣¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ÁÙ´²ÊµÑ鼯»®¼°Êý¾Ý»ã×Ü

 

ÁÙ´²Ò©´ú¶¯Á¦Ñ§Êý¾Ý£¨PK£©ÏÔʾBZE2204 CAR-T²úÆ·¼«¸ßµÄÌåÄÚÀ©ÔöÄÜÁ¦¡£¡£¡£¡£¡£¡£ÓëÆäËûCAR-T¿ìËÙ¹¤ÒÕÀàËÆ£¬£¬£¬£¬£¬ £¬BZE2204²úÆ·´ï·åʱ¼ä£¨Tmax£©Îªd14×óÓÒ£¬£¬£¬£¬£¬ £¬µ«ÒÔµÍÓÚÊÐÊÛ²úÆ·1/40µÄ¼ÁÁ¿ÏµִïͨÀý¼ÁÁ¿²úÆ·30-200±¶µÄ Cmax (CAR-T/ul), ÒÔ¼°17-150±¶µÄAUC(CAR-T/ul*d)£¬£¬£¬£¬£¬ £¬ÇÒ¶¾¸±×÷ÓÃС£¡£¡£¡£¡£¡£¬£¬£¬£¬£¬ £¬ÎÞ3¼¶»òÒÔÉϵÄCRS£¬£¬£¬£¬£¬ £¬ÎÞDLT£¬£¬£¬£¬£¬ £¬Õ¹Ê¾Á˲úÆ·¸ßЧµÍ¶¾µÄÀ©Ôöģʽ¡£¡£¡£¡£¡£¡£

£¨ÊÐÊÛÊý¾Ý¾ùÀ´×Ô¹ûÕæ½ÒÏþµÄ²Î¿¼ÎÄÏ×£©

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ÁÙ´²Ò©´ú¶¯Á¦Ñ§Êý¾Ý»ã×ܼ°ÓëÊÐÊÛ²úÆ·±ÈÕÕ

 

´ú±íÐÔ»¼ÕßÁÙ´²Êý¾ÝÏÔʾV-30hºÍV-6hµÄ»¼ÕߵĻùÏßÊý¾ÝºÍÔÚ½ÓÊÜBZE2204 JL-Lightning CAR-TÖÎÁƺóµÄËæ·ÃÆÚµÄPET-CTͼ¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»¼ÕßÔÚ½ÓÊÜBZE2204²úÆ·»ØÊäºó£¬£¬£¬£¬£¬ £¬ÔÚ28ÌìÄÚ¼´µÖ´ïÖ×ÁöÍêÈ«»º½â(CR)£¬£¬£¬£¬£¬ £¬²¢ÔÚºóËæ·ÃÆÚÖлñµÃÒ»Á¬»º½â¡£¡£¡£¡£¡£¡£×èÖ¹ÏÖÔڸüÁÁ¿ÏÂV-30h»¼Õß×î³¤Ëæ·ÃÆÚΪ6¸öÔ£¬£¬£¬£¬£¬ £¬V-6h×黼Õß×î³¤Ëæ·ÃÆÚΪ3¸öÔ£¬£¬£¬£¬£¬ £¬ºóÐøÊý¾Ý½«Ò»Á¬¸üС£¡£¡£¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Í¼ ´ú±íÐÔ»¼ÕßÁÙ´²PET-CTÊý¾Ýչʾ£¨V-30hÓëV-6h£©

 

½áÂÛ£º

1. JL-Lighting CAR-T ÎÞ×÷Óý³¬¿ìËÙÆ½Ì¨¹¤ÒÕ´îÔØJLת×ùø¼°Ì«ÖÊÁ£ÏµÍ³£¬£¬£¬£¬£¬ £¬Õ¹Ê¾Á˷Dz¡¶¾¹¤ÒÕϸßЧµÍ¶¾¡¢¸ß»îµÍ·Ö½âµÄÁìÏȵÄCAR-TÖÆ±¸¹¤ÒÕ¡£¡£¡£¡£¡£¡£

2.ÁÙ´²Ç°Êý¾Ý֤ʵÎúBZE2204 CAR-T²úÆ·ÔÚСÊóÌåÄÚ¸ßÔöֵDZÁ¦¡¢¸ßÖ×ÁöÒÖÖÆÐ§Âʼ°¸ßÇå¾²ÐÔµÄÌØµã£¬£¬£¬£¬£¬ £¬ÇкÏÁÙ´²Ç°ÆÀ¹ÀµÄÔ¤ÆÚ¡£¡£¡£¡£¡£¡£

3. ÏÖÓÐÁÙ´²Êý¾ÝչʾBZE2204 ÓµÓм«¸ßµÄÒ©´ú¶¯Á¦Ñ§À©ÔöÄÜÁ¦£¨PK£©ºÍÔÚ¼«µÍ¼ÁÁ¿ÏÂÓÅÒìµÄÌåÄÚÁÆÐ§£¨ORR=100%£¬£¬£¬£¬£¬ £¬CR>67%£©.ÁÙ´²ÊµÑ黹ÔÚ½øÒ»²½¿ªÕ¹ÖС£¡£¡£¡£¡£¡£

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾
·µ»Ø¶¥²¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿